Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Celma, Ana (Hospital Universitari Vall d'Hebron)
Planas, Jacques (Hospital Universitari Vall d'Hebron)
Placer, José (Hospital Universitari Vall d'Hebron)
de Torres, Inés (Hospital Universitari Vall d'Hebron)
Olivan, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Carles, Joan (Universitat Internacional de Catalunya. Departament de Ciències Bàsiques)
Reventós, Jaume (Institut d'Investigació Biomèdica de Bellvitge)
Doll, Andreas (Universitat Internacional de Catalunya. Departament de Ciències Bàsiques)

Date:	2014
Abstract:	The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30. 9% of those studied. The PCa detection rate was 31. 2% of men on statins and 37% of non-statin users (p < 0. 006). The PCa detection rate was 26. 3% in men with NSC and 40. 6% in those with HSC (p < 0. 001). In the subset of NSC men, the PCa rate was 26. 5% for statin users and 26. 2% for non-users (p = 0. 939), while in men with HSC, the PCa rate was 36. 4% for statin users and 42. 0% for non-statin users (p = 0. 063). The HGPCa rate was 41. 8% for statin users and 32. 5% for non-users (p = 0. 012). NSC men had a 53. 8% rate of HGPCa, while the rate was only 27. 6% in HSC men (p < 0. 001). NSC men on statins had an HGPCa rate of 70. 2%, while non-statin users had a rate of 41. 2% (p < 0. 001). The HGPCa rate for HSC men on statins was 18. 8%, while the rate was 30. 0% (p = 0. 011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1. 87 (95% CI 1. 56-2. 24) and HGPCa risk, OR 0. 31 (95% CI 0. 23-0. 44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol.
Grants:	Ministerio de Ciencia e Innovación RTICC RD12-0036-0035 Instituto de Salud Carlos III PI13-00173 Agència de Gestió d'Ajuts Universitaris i de Recerca SGR00487
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Statins ; Cholesterol ; Prostate cancer risk ; Prostate cancer aggressiveness
Published in:	International journal of molecular sciences, Vol. 15 (august 2014) , p. 13615-13623, ISSN 1422-0067

DOI: 10.3390/ijms150813615
PMID: 25101846

9 p, 695.8 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles